<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2014-02-23">23 February 2014</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Andreas</forename><surname>Andreou</surname></persName>
							<email>andreas.andreou@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Safak</forename><surname>Gül</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Pascher</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wenzel</forename><surname>Schöning</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hussein</forename><surname>Al-Abadi</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marcus</forename><surname>Bahra</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fritz</forename><surname>Klein</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Timm</forename><surname>Denecke</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Diagnostic and Interventional Radiology</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Benjamin</forename><surname>Strücker</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gero</forename><surname>Puhl</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johann</forename><surname>Pratschke</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Seehofer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of General, Visceral and Transplant Surgery</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum, Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2014-02-23">23 February 2014</date>
						</imprint>
					</monogr>
					<idno type="MD5">D150B88C7B57C5AB21184C9BC9170BEB</idno>
					<idno type="DOI">10.1111/hpb.12345</idno>
					<note type="submission">Received 31 March 2014; accepted 22 August 2014</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:19+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Patients with hepatocellular carcinoma (HCC) beyond the Milan criteria are not considered for liver transplantation (LT) in many centres; however, LT may be the only treatment able to achieve long-term survival in patients with unresectable HCC.</s><s>The aim of this study was to assess the role of recipient age and tumour biology expressed by the DNA index in the selection of HCC patients for LT.</s></p><p><s>Patients: Clinicopathological data of 364 patients with HCC who underwent LT between 1989 and 2010 were evaluated.</s><s>Overall survival (OS) was analysed by patient age, tumour burden based on Milan criteria and the DNA index.</s></p><p><s>Results: After a median follow-up time of 78 months, the median survival was 100 months.</s><s>Factors associated with OS on univariate analysis included Milan criteria, patient age, hepatitis C infection, alpha-fetoprotein (AFP) level, the DNA index, number of HCC, diameter of HCC, bilobar HCC, microvascular tumour invasion and tumour grading.</s><s>On multivariate analysis, HCC beyond Milan criteria and the DNA index &gt;1.5 independently predicted a worse OS.</s><s>When stratifying patients by both age and Milan criteria, patients ≤60 years with HCC beyond Milan criteria had an OS comparable to that of patients &gt;60 years within Milan criteria (10-year OS: 33% versus 37%, P = 0.08).</s><s>Patients ≤60 years with HCC beyond Milan criteria but a favourable DNA index ≤1.5 achieved excellent long-term outcomes, comparable with those of patients within Milan criteria.</s><s>Conclusions: Patients ≤60 years may undergo LT for HCC with favourable outcomes independently of their tumour burden.</s><s>Additional assessment of tumour biology, e.g. using the DNA index, especially in this subgroup of patients can support the selection of LT candidates who may derive the most long-term survival benefit, even if Milan criteria are not fulfilled.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Since the implementation of the Milan criteria, 1 liver transplantation (LT) has been established as the preferred treatment for patients with end-stage liver disease and hepatocellular carcinoma (HCC) resulting in survivals comparable to those of LT recipients with a benign disease.</s><s>3]<ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> Extended criteria such as The University of California, San Francisco (UCSF) criteria, <ref type="bibr" target="#b5">6</ref> the Tokyo criteria, <ref type="bibr" target="#b6">7</ref> the Asan criteria <ref type="bibr" target="#b7">8</ref> and the 'up to seven criteria' <ref type="bibr" target="#b8">9</ref> have been introduced with the aim of improving the selection of appropriate liver transplant recipients among patients with advanced HCC; however, such classifications focused on morphological characteristics underestimating the physical status and age of the patient or the tumour biology.</s></p><p><s>Previous studies showed that patient age is associated with overall survival (OS) after LT for HCC, <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref> or LT in general <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> and a cut-off age of &gt;60 years <ref type="bibr" target="#b10">11</ref> or &gt;65 years <ref type="bibr" target="#b14">15</ref> has been frequently identified as a predictor of worse survival.</s><s>This finding is also confirmed by the long-term data of the European liver transplant registry showing significantly better survivals for patients younger than 60 years who were treated with LT in Europe between 1988 and 2011 (10-year OS rate: 66% for 15-to 45-year-old patients versus 59% for 45-to 60-year-old patients versus 50% for &gt;60year-old patients, P &lt; 0.0001) (European Liver Transplant Registry).</s><s>The importance of patient age when evaluating LT candidates is underlined by the fact that a significant number of patients who undergo LT in Europe and the USA are older than 60 years.</s><s>According to the OPTN &amp; SRTR Annual Data Report 2011, 64% of patients who underwent LT in the USA in 2011 were between 50 and 64 years old and 13% of the patients were ≥65 years old.</s><s>Similarly, 37% of patients treated with LT in Europe in 2011 were between 56 and 64 years old and 13% of the patients were ≥65 years old (Eurotransplant Annual Report 2011).</s><s>The trend to transplant patients older than 60 years has been increasing over the last 30 years, from &lt;5% in the 1980s to 25% in 2011, and one-fourth of these patients were suffering from cancer disease mainly HCC being the primary disease leading to LT (European Liver Transplant Registry).</s></p><p><s>In addition to the assessment of patient biology when evaluating LT candidates, tumour biology could play a decisive role in the selection of patients with advanced HCC who may achieve favourable long-term survivals.</s><s>Recent studies have described the DNA index as an objective tool to express tumour biology.</s><s>This tumour marker is defined as the ratio of the DNA content of tumour cells to the DNA content of the diploid reference cells and cut-off values ≤1.5, ≤1.4 and ≤2 have been reported to be associated with favourable biology and improved survivals after LT for HCC, <ref type="bibr" target="#b15">16</ref> liver resection for intrahepatic cholangiocarcinoma <ref type="bibr" target="#b16">17</ref> and resection of adenocarcinoma of the pancreatic head, 18 respectively.</s></p><p><s>The objective of this study was to analyse the OS of patients who underwent LT for HCC in a high-volume transplant centre and identify factors associated with improved outcomes.</s><s>We additionally aimed to assess the role of recipient age and tumour biology in the selection of appropriate LT candidates beyond tumour burden criteria.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient inclusion criteria</head><p><s>After Institutional Review Board approval, clinicopathological data of 364 consecutive patients with HCC who underwent LT between 1989 and 2010 at the Charité Campus Virchow-Klinikum in Berlin, Germany, were prospectively collected and reviewed.</s><s>Patients without a histological confirmation of HCC in the explanted liver and patients with fibrolamellar HCC were excluded from the study.</s><s>Paediatric patients (&lt;18 years) were not included in the analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pre-operative assessment</head><p><s>The pre-operative assessment included medical history, physical examination, serum laboratory tests, imaging studies and an anaesthesia evaluation.</s><s>Multiphase contrast-enhanced computed tomography with liver protocol <ref type="bibr" target="#b18">19</ref> was used to define the extent and location of HCC and to rule out macrovascular tumour invasion and the presence of extrahepatic disease.</s><s>The diagnosis was confirmed by one additional imaging method (magnetic resonance imaging or ultrasonography) or percutaneous biopsy.</s><s>Decision making for listing patients for LT was based on case presentations attended by liver transplant surgeons, transplant hepatologists and radiologists.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Surgical procedure</head><p><s>Orthotopic LT was performed using a standardized approach with inferior vena cava interposition or the piggyback technique.</s><s>Reperfusion was started after the completion of the end-to-end anastomoses of the portal vein and the hepatic artery.</s><s>Subsequently, venting was started via the inferior cava vein.</s><s>The remaining anastomoses were performed after haemostasis had been achieved. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref></s><s>Side-to-side choledochocholedochostomy was performed, and a T-tube was placed in the common bile duct of the recipient. <ref type="bibr" target="#b21">22</ref></s><s>st-operative management Post-operative mortality was defined as any in-hospital death after LT, and post-operative morbidity was defined as any complication within 90 days.</s></p><p><s>All specimens were histologically examined to confirm the diagnosis of HCC, and evaluate the tumour grading.</s><s>Pathological specimens were also examined to identify microvascular invasion, which was defined as gross or microscopic involvement of the lobar or segmental branches of the portal or hepatic veins as well as the presence of tumor emboli within the central hepatic vein, the portal vein or the large capsular vessels. <ref type="bibr" target="#b22">23</ref></s><s>7]<ref type="bibr">[18]</ref> A DNA index ≤1.5 was used to define favourable tumour biology in this study as previously reported. <ref type="bibr" target="#b15">16</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Quantitative and qualitative variables were expressed as medians (range) and frequencies.</s><s>Comparisons between groups were analysed with the chi-square or Fisher's exact test for categorical variables and the Mann-Whitney U-test for continuous variables, as appropriate.</s><s>Patients were stratified by their age and the clinicopathological characteristics of patients 60 years old or younger were compared with those of patients older than 60 years.</s><s>Moreover, the relationship between the DNA index and other surrogate factors for tumour biology was investigated.</s><s>OS was calculated from the date of LT to the date of death or last follow-up using the Kaplan-Meier method.</s><s>The recurrence rate was also calculated from the date of LT to the date of first recurrence.</s><s>Patients without recurrence were censored at the date of last follow-up or patient death without tumour recurrence.</s><s>Log-rank tests were used to assess significance for univariate analyses.</s></p><p><s>To identify factors associated with OS of patients undergoing LT for HCC, the following clinicopathological variables were recorded and analysed: recipient gender (male versus female), recipient age (≤60 versus &gt;60 years), donor age (≤60 versus &gt;60 years), donor gender (male versus female), hepatitis C infection (yes versus no), Child-Pugh classification (A versus B and C), alpha-fetoprotein level (AFP) (≤400 versus &gt;400 ng/ml), neoadjuvant treatment with transarterial chemoembolization (TACE) (yes versus no), number of HCC (&gt;3 versus ≤3), largest diameter of HCC (&gt;5 cm versus ≤5 cm), Milan criteria (beyond versus within), bilobar HCC (yes versus no), DNA index (&gt;1.5 versus ≤1.5), microvascular tumour invasion (yes versus no), tumour grading (G1 and G2 versus G3), acute rejection (yes versus no) and post-LT complications (yes versus no).</s><s>All variables associated with survival with P &lt; 0.05 in the univariate analysis were subsequently entered into a Cox multivariate regression model with backward elimination.</s><s>P-values &lt; 0.05 were considered statistically significant.</s><s>Statistical analyses were performed using the SPSS software package, version 20 (IBM, Armonk, NY, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient characteristics</head><p><s>During the study period, 364 patients with HCC underwent LT.</s><s>Patient characteristics of the entire study cohort are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s>The median age was 58 years (21-69), and 82% of the patients were male.</s><s>HCC burden fulfilled the Milan criteria in 59% of patients and 31% of patients had a DNA index &gt;1.5.</s><s>Clinicopathological characteristics by patient age (≤60 versus &gt;60 years) were also summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Patients in both subgroups had comparable peri-operative and tumour characteristics.</s><s>No significant differences could be identified between the two groups regarding the percentage of patients suffering from a chronic hepatitis C infection or the degree of chronic liver disease according to the Child-Pugh score.</s><s>Neoadjuvant treatment with TACE was performed independently from patient age.</s><s>There was also no association between patient age and the number of HCC, diameter of HCC, tumour grading or the presence of microvascular tumor invasion.</s><s>Post-LT morbidity and mortality did not significantly differ between patients ≤60 and patients &gt;60 years old (P = 0.773 and P = 0.079, respectively).</s><s>The two groups were different in respect to the incidence of acute rejection after LT which was higher among younger patients.</s><s>However, this had no impact on the rate of primary graft dysfunction and the need for re-transplantation between the two groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association between the DNA index and surrogate factors for tumour biology</head><p><s>The DNA index was significantly associated with AFP level &gt;400 ng/ml (P = 0.014), poor tumour differentiation (G3) (P = 0.026), largest diameter of HCC &gt;5 cm (P = 0.041), number of HCC &gt;3 (P = 0.003) and microvascular invasion (P &lt; 0.0001).</s></p><p><s>Long-term outcomes and predictors of OS After a median follow-up time of 78 months (1-235), the median survival of all patients who underwent LT for HCC (n = 364) was 100 months.</s><s>Univariate and multivariate analyses for predictors of OS in HCC patients after LT are summarized in Table <ref type="table" target="#tab_1">2</ref>. On univariate analysis, factors associated with worse OS included recipient age &gt;60 years (P &lt; 0.0001), hepatitis C infection (P = 0.032), AFP level &gt;400 ng/ml (P = 0.004), number of HCC &gt;3 cm (P &lt; 0.0001), diameter of the largest HCC &gt;5 cm (P &lt; 0.0001), HCC beyond Milan criteria (P &lt; 0.0001), bilobar HCC (P = 0.002), a DNA index &gt;1.5 (P &lt; 0.0001), microvascular invasion (P &lt; 0.0001) and tumour grading G3 (P &lt; 0.0001).</s><s>The number of HCC and diameter of the largest HCC were not included in the multivariate analysis in order to avoid the effect of covariance.</s><s>On multivariate analysis, only HCC beyond Milan criteria [hazard ratio (HR) 1.69, 95% confidence interval (CI) 1.17-2.44,</s><s>P = 0.005] and a DNA index &gt;1.5 (HR 4.22, 95% CI 2.89-6.17,</s><s>P &lt; 0.0001) were independently associated with worse OS.</s><s>Tumour recurrence was the most frequent cause of death among patients with a DNA index &gt;1.5 (59%, P = 0.002).</s><s>De novo malignancies were responsible for 12% of deaths in this subgroup, and the remaining 29% of patients with a DNA index &gt;1.5 died as a result of cardiovascular, pulmonary or infectious complications.</s></p><p><s>When stratifying patients by both age and Milan criteria, patients ≤60 years with HCC beyond Milan criteria had an OS after 10 years comparable to that of older patients within Milan criteria (33% versus 37%, P = 0.08; Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Further assessment of tumour biology using a DNA index for younger patients with advanced disease showed that recipients ≤60 years old with HCC beyond Milan criteria but a favourable DNA index ≤1.5 had excellent OS (10-year OS rate 59%; Fig. <ref type="figure" target="#fig_1">2</ref>), comparable to that of all patients within Milan criteria.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This study analysed the outcomes of patients with HCC who underwent LT in a major transplant centre and indicated that patient and tumour biology have a significant impact on OS.</s><s>Consequently, assessment of both patient age and DNA index may support the selection of patients to undergo LT for HCC with promising long-term results independently of the extent of their tumour burden as this is described by the Milan criteria, or other extended criteria.</s></p><p><s>Univariate analysis for predictors of OS in the study cohort identified among other factors patient age, Milan criteria and DNA index to be significantly associated with OS.</s><s>On the multivariate analysis, HCC beyond Milan criteria and a DNA index &gt;1.5 independently predicted worse OS.</s><s>Subsequent survival analysis by stratifying patients by both age and Milan criteria showed that patients ≤60 years old within Milan criteria had the best OS (10-year OS rate 68%) whereas patients &gt;60 years old beyond Milan criteria had a significantly diminished 10-year survival rate of only 6%.</s><s>Interestingly, we could show that there was no significant difference in 10-year survival between patients ≤60 years beyond Milan criteria and patients &gt;60 years within Milan criteria (33% versus 37%, P = 0.08), despite the tendency for improved survival among older patients within Milan criteria observed 5 years after LT, indicating that favourable patient biology might counterbalance the negative effect of advanced disease on long-term outcome.</s><s>Evaluation of the risk for HCC recurrence in our study cohort showed that patients &gt;60 years old with HCC within the Milan criteria had a lower risk for tumour recurrence than patients ≤60 years old beyond Milan criteria (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>This confirms our hypothesis that younger patients beyond Milan criteria may have comparable OS to older patients within Milan criteria in spite of diverging recurrence rates owing to the different co-morbidity profiles between the two groups.</s><s>Further assessment of tumour biology using the DNA index in the subset of patients ≤60 years old with a HCC burden beyond Milan criteria showed that if tumour biology was favourable as defined by a DNA index ≤1.5 the OS was excellent and comparable to the survival of patients who fulfilled the Milan criteria.</s></p><p><s>Our study confirms previous studies showing that younger patients may have significantly better long-term survivals after LT for HCC than patients older than 60 years <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11</ref> or 65 years. <ref type="bibr" target="#b14">15</ref></s><s>Based on our findings, we do not intend to advocate the opinion that LT should be denied to elderly patients within Milan criteria but rather underline the need for more careful evaluation of younger patients who may not be considered for LT if they do not fulfill the Milan criteria.</s><s>Decision making in such borderline cases can be supported by the evaluation of tumour biology, e.g. using the DNA index.</s><s>The combination of less aggressive tumour biology and younger age, which in many cases implies a better physical status, less comorbidities, a better tolerance towards treatments for eventual recurrence <ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref> and a lower risk for the development of de novo malignancies, <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29</ref> may provide the most promising probability for achieving prolonged OS after LT independently of conventional criteria based on the number and size of tumour nodules.</s><s>Therefore, according to our selection algorithm for LT (Fig. <ref type="figure" target="#fig_3">4</ref>), we recommend a percutaneous biopsy from the dominant lesion during the pre-operative evaluation of LT candidates ≤60 years with HCC beyond the Milan criteria but, e.g.</s><s>within the UCSF criteria to assess the DNA index.</s><s>Patients with a DNA index ≤1.5 and favorable tumour biology could be considered for a living-donor LT.</s><s>The risk for tumour seeding after biopsy <ref type="bibr" target="#b29">30</ref> in HCC patients is present but relatively low.</s><s>However, we think that the net benefit of examination of the biopsy with determination of the DNA index is still given, as it provides a valuable selection tool for LT for patients with HCC beyond the Milan criteria.</s></p><p><s>Our present retrospective study has some limitations.</s><s>The long study period of 21 years may imply disparities in the surgical technique and peri-operative management between the different time periods.</s><s>However, patient care under the guidance of transplant surgeons with experience of more than 20 years in the field and the large volume of patients being transplanted in our centre every year have contributed to a consistent state-of-the-art patient treatment over the entire study period.</s><s>Another potential limitation are the possible changes in the biological age and life expectancy between the different time periods with an expected slower progression of the biological age and an increase of lifeexpectancy over the study period.</s><s>However, the impact these changes might have had on survival after LT has been possibly counterbalanced by the concomitantly increasing number of patients &gt;60 years old undergoing LT in the most recent years.</s><s>A potential bias regarding the survival differences between the two patient groups stratified by age (≤60 versus &gt;60 years) might have been related to the utilization of neoadjuvant treatment with TACE.</s><s>Nevertheless, our comparative analysis between the two groups showed that since the implementation of this therapy, patients with HCC on the waiting list were treated with TACE before LT independently of their age.</s></p><p><s>In conclusion, this study indicates that patients 60 years old or younger may undergo LT for HCC with favourable outcomes even if they do not fulfill the very restrictive Milan criteria.</s><s>Additional assessment of tumour biology, e.g. using DNA cytometry, within this subset of patients can contribute to the better selection of</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Overall survival (OS) according to age and Milan criteria (MC) in 364 patients with hepatocellular carcinoma (HCC) who underwent liver transplantation</s></p></div></figDesc><graphic coords="6,64.76,308.41,156.43,111.17" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Overall survival (OS) according to the DNA index in 98 patients ≤60 years old with hepatocellular carcinoma (HCC) beyond Milan criteria (MC) who underwent liver transplantation</s></p></div></figDesc><graphic coords="6,345.02,290.05,189.89,143.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Recurrence rate (RR) according to age and Milan criteria (MC) in 364 patients with hepatocellular carcinoma (HCC) who underwent liver transplantation</s></p></div></figDesc><graphic coords="7,85.96,126.88,149.82,88.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 4</head><label>4</label><figDesc><div><p><s>Figure 4 Selection algorithm for liver transplantation</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Clinicopathological characteristics of 364 patients who underwent liver transplantation for hepatocellular carcinoma (HCC)</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell>All patients</cell><cell>Age ≤60 years</cell><cell>Age &gt;60 years</cell><cell>P a</cell></row><row><cell></cell><cell>(n = 364)</cell><cell>(n = 249)</cell><cell>(n = 115)</cell><cell></cell></row><row><cell>Male gender, n (%)</cell><cell>297 (82)</cell><cell>206 (83)</cell><cell>91 (79)</cell><cell>0.410</cell></row><row><cell>Median donor age (range), years</cell><cell>50 (8-91)</cell><cell>49 (13-84)</cell><cell>52 (8-91)</cell><cell>0.265</cell></row><row><cell>Male donor, n (%)</cell><cell>207 (57)</cell><cell>147 (59)</cell><cell>60 (52)</cell><cell>0.193</cell></row><row><cell>Hepatitis C, n (%)</cell><cell>125 (34)</cell><cell>82 (33)</cell><cell>43 (37)</cell><cell>0.405</cell></row><row><cell>Median ischemia time (range), hours</cell><cell>10 (1-21)</cell><cell>9 (1-21)</cell><cell>10 (1-19)</cell><cell>0.124</cell></row><row><cell>Median ICU stay of donor(range), days</cell><cell>3 (0-25)</cell><cell>3 (0-25)</cell><cell>3 (0-23)</cell><cell>0.188</cell></row><row><cell>Child-Pugh class B/C, n (%)</cell><cell>207 (57)</cell><cell>147 (59)</cell><cell>60 (52)</cell><cell>0.239</cell></row><row><cell>Median AFP (range), ng/ml</cell><cell>16 (1-108195)</cell><cell>17 (1-108195)</cell><cell>15 (1-46100)</cell><cell>0.457</cell></row><row><cell>TACE, n (%)</cell><cell>97 (27)</cell><cell>61 (25)</cell><cell>36 (31)</cell><cell>0.172</cell></row><row><cell>Median number of HCC (range)</cell><cell>1 (1-12)</cell><cell>1 (1-12)</cell><cell>2 (1-10)</cell><cell>0.322</cell></row><row><cell>Median largest diameter of HCC (range), cm</cell><cell>3 (0.5-20)</cell><cell>3 (0.5-20)</cell><cell>3 (1-15)</cell><cell>0.099</cell></row><row><cell>Within Milan criteria, n (%)</cell><cell>214 (59)</cell><cell>150 (60)</cell><cell>64 (56)</cell><cell>0.408</cell></row><row><cell>Bilobar HCC, n (%)</cell><cell>94 (26)</cell><cell>60 (24)</cell><cell>34 (29)</cell><cell>0.358</cell></row><row><cell>Median DNA index (range)</cell><cell>1.2 (0.88-2.7)</cell><cell>1.3 (0.9-2.7)</cell><cell>1.2 (0.88-2.6)</cell><cell>0.372</cell></row><row><cell>Microvascular invasion, n (%)</cell><cell>118 (32)</cell><cell>82 (33)</cell><cell>36 (31)</cell><cell>0.798</cell></row><row><cell>Grading 3, n (%)</cell><cell>87 (24)</cell><cell>57 (23)</cell><cell>30 (26)</cell><cell>0.453</cell></row><row><cell>Acute rejection, n (%)</cell><cell>95 (26)</cell><cell>75 (30)</cell><cell>20 (17)</cell><cell>0.011</cell></row><row><cell>Median number of intraoperative transfusions (range)</cell><cell>4 (0-60)</cell><cell>4 (0-60)</cell><cell>2 (0-16)</cell><cell>0.004</cell></row><row><cell>Post-LT complications, n (%)</cell><cell>51 (14)</cell><cell>34 (14)</cell><cell>17 (15)</cell><cell>0.773</cell></row><row><cell>In-hospital mortality, n (%)</cell><cell>10 (2.7)</cell><cell>4 (1.6)</cell><cell>6 (5.2)</cell><cell>0.079</cell></row></table><note><p><s>a Comparison of patients ≤60 years with patients &gt;60 years.</s><s>LT, liver transplantation; AFP, alpha-Fetoprotein; TACE, transarterial chemoembolization; ICU, intensive care unit.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Univariate and multivariate analysis of clinicopathological variables associated with overall survival in 364 patients who underwent liver transplantation for hepatocellular carcinoma (HCC)</s></p></div></figDesc><table><row><cell>Variable</cell><cell>%</cell><cell>Median survival</cell><cell>Univariate</cell><cell cols="2">Multivariate analysis a</cell></row><row><cell></cell><cell></cell><cell>(months)</cell><cell>analysis</cell><cell>P</cell><cell>Hazard Ratio</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(95% CI)</cell></row><row><cell>Recipient gender</cell><cell></cell><cell></cell><cell>0.492</cell><cell></cell></row><row><cell>Male</cell><cell>82</cell><cell>97</cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell>18</cell><cell>130</cell><cell></cell><cell></cell></row><row><cell>Recipient age, years</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell><cell>NS</cell></row><row><cell>≤60</cell><cell>68</cell><cell>147</cell><cell></cell><cell></cell></row><row><cell>&gt;60</cell><cell>32</cell><cell>61</cell><cell></cell><cell></cell></row><row><cell>Donor age, years</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤60</cell><cell>73</cell><cell>108</cell><cell>0.570</cell><cell></cell></row><row><cell>&gt;60</cell><cell>27</cell><cell>69</cell><cell></cell><cell></cell></row><row><cell>Donor gender</cell><cell></cell><cell></cell><cell>0.839</cell><cell></cell></row><row><cell>Male</cell><cell>57</cell><cell>105</cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell>43</cell><cell>94</cell><cell></cell><cell></cell></row><row><cell>Hepatitis C</cell><cell></cell><cell></cell><cell>0.032</cell><cell>NS</cell></row><row><cell>Yes</cell><cell>34</cell><cell>74</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>66</cell><cell>132</cell><cell></cell><cell></cell></row><row><cell>Child-Pugh classification</cell><cell></cell><cell></cell><cell>0.297</cell><cell></cell></row><row><cell>A</cell><cell>4 3</cell><cell>9 6</cell><cell></cell><cell></cell></row><row><cell>B and C</cell><cell>57</cell><cell>125</cell><cell></cell><cell></cell></row><row><cell>AFP level</cell><cell></cell><cell></cell><cell>0.004</cell><cell>NS</cell></row><row><cell>&gt;400 ng/ml</cell><cell>14</cell><cell>61</cell><cell></cell><cell></cell></row><row><cell>≤400 ng/ml</cell><cell>86</cell><cell>125</cell><cell></cell><cell></cell></row><row><cell>TACE</cell><cell></cell><cell></cell><cell>0.848</cell><cell></cell></row><row><cell>Yes</cell><cell>27</cell><cell>80</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>73</cell><cell>101</cell><cell></cell><cell></cell></row><row><cell>Number of HCC</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell><cell></cell></row><row><cell>&gt;3</cell><cell>1 6</cell><cell>3 6</cell><cell></cell><cell></cell></row><row><cell>≤3</cell><cell>84</cell><cell>125</cell><cell></cell><cell></cell></row><row><cell>Largest diameter of HCC</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell><cell></cell></row><row><cell>&gt;5 cm</cell><cell>18</cell><cell>40</cell><cell></cell><cell></cell></row><row><cell>≤5 cm</cell><cell>82</cell><cell>125</cell><cell></cell><cell></cell></row><row><cell>Milan criteria (histology)</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell><cell>0.005</cell></row><row><cell>Beyond</cell><cell>41</cell><cell>44</cell><cell></cell><cell></cell><cell>1.69 (1.17-2.44)</cell></row><row><cell>Within</cell><cell>59</cell><cell>170</cell><cell></cell><cell></cell></row><row><cell>Bilobar HCC</cell><cell></cell><cell></cell><cell>0.002</cell><cell>NS</cell></row><row><cell>Yes</cell><cell>26</cell><cell>51</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>74</cell><cell>125</cell><cell></cell><cell></cell></row><row><cell>DNA index</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell><cell>&lt;0.0001</cell></row><row><cell>&gt;1.5</cell><cell>30</cell><cell>27</cell><cell></cell><cell></cell><cell>4.22 (2.89-6.17)</cell></row><row><cell>≤1.5</cell><cell>70</cell><cell>176</cell><cell></cell><cell></cell></row><row><cell>Microvascular invasion</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell><cell>NS</cell></row><row><cell>Yes</cell><cell>32</cell><cell>56</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>68</cell><cell>158</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 Continued</head><label>2</label><figDesc></figDesc><table><row><cell>Variable</cell><cell>%</cell><cell>Median survival</cell><cell>Univariate</cell><cell cols="2">Multivariate analysis a</cell></row><row><cell></cell><cell></cell><cell>(months)</cell><cell>analysis</cell><cell>P</cell><cell>Hazard Ratio</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(95% CI)</cell></row><row><cell>Grading</cell><cell></cell><cell></cell><cell>&lt;0.0001</cell><cell>NS</cell></row><row><cell>G1 and G2</cell><cell>76</cell><cell>125</cell><cell></cell><cell></cell></row><row><cell>G3</cell><cell>24</cell><cell>51</cell><cell></cell><cell></cell></row><row><cell>Acute rejection</cell><cell></cell><cell></cell><cell>0.851</cell><cell></cell></row><row><cell>Yes</cell><cell>26</cell><cell>117</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>74</cell><cell>96</cell><cell></cell><cell></cell></row><row><cell>Post-LT complications</cell><cell></cell><cell></cell><cell>0.196</cell><cell></cell></row><row><cell>Yes</cell><cell>14</cell><cell>61</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>86</cell><cell>108</cell><cell></cell><cell></cell></row></table><note><p><s>a Cox regression multivariate analysis included all variables with P &lt; 0.05 in univariate analysis.</s><s>CI, confidence interval; LT, liver transplantation; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization; NS, not significant.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">HPB 2015, 17, 168-175 © 2014 International Hepato-Pancreato-Biliary Association</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>patients with HCC who may derive the most long-term survival benefit from LT beyond Milan criteria.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of interest</head><p><s>None declared.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Mazzaferro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Regalia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Doci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Andreola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pulvirenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bozzetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">334</biblScope>
			<biblScope unit="page" from="693" to="699" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Kneteman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oberholzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Al</forename><surname>Saghier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meeberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Blitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1301" to="1311" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Takada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ueda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sakamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Haga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Maetani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dig Dis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="299" to="302" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Liver transplantation in patients with hepatocellular carcinoma across Milan criteria</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sangro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Quiroga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Inarrairaegui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rotellar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="272" to="278" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria</title>
		<author>
			<persName><forename type="first">C</forename><surname>Duvoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Roudot-Thoraval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Decaens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pessione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Badran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Piardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="e914" to="985" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">Y</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ferrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Bass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bacchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Venook</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1394" to="1403" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sugawara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Makuuchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dig Dis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="310" to="312" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Sung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="935" to="945" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Mazzaferro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Llovet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Miceli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhoori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiavo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mariani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="35" to="43" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Suh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">B</forename><surname>Cho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="598" to="609" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor</title>
		<author>
			<persName><forename type="first">E</forename><surname>Vibert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Azoulay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hoti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Iacopinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Salloum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="129" to="137" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Age and liver transplantation: a report of the Liver Transplantation Database</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Zetterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Belle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Hoofnagle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lawlor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Everhart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="500" to="506" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Selzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kashfi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Selzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mccluskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Greig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Cattral</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1288" to="1295" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Liver transplantation in the United States</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Thuluvath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Guidinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Fung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Rayhill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pelletier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1003" to="1019" />
			<date type="published" when="1999">2010. 1999-2008</date>
		</imprint>
	</monogr>
	<note>Pt 2</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Increased long-term survival among patients with hepatocellular carcinoma after implementation of model for end-stage liver disease score</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Devaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cho-Phan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1534" to="1540" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jonas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Al-Abadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Benckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hippler-Benscheid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Saribeyoglu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">250</biblScope>
			<biblScope unit="page" from="1008" to="1013" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The DNA index is a strong predictive marker in intrahepatic cholangiocarcinoma: the results of a five-year prospective study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kamphues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Al-Abadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Durr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Klauschen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stenzinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surg Today</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1336" to="1342" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">adenocarcinoma of the pancreatic head: results of a 5-year prospective study</title>
	</analytic>
	<monogr>
		<title level="j">Pancreas</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="807" to="812" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Multislice computed tomography using a triple-phase contrast protocol for preoperative assessment of hepatic tumor load in patients with hepatocellular carcinoma before liver transplantation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Denecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grieser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Froling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Steffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rudolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Stelter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Int</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="395" to="402" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Donor age does not influence 12-month outcome after orthotopic liver transplantation</title>
		<author>
			<persName><forename type="first">W</forename><surname>Faber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Seehofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Puhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Guckelberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bertram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Neuhaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Proc</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="3789" to="3795" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Technical feasibility of liver transplantation without cold storage</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Puhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Neuhaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Langenbecks Arch Surg</title>
		<imprint>
			<biblScope unit="volume">399</biblScope>
			<biblScope unit="page" from="127" to="133" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">transplantation: a prospective randomized trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ulrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pascher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stockmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">250</biblScope>
			<biblScope unit="page" from="766" to="771" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Simplified staging for hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Vauthey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lauwers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Esnaola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Do</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Belghiti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mirza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1527" to="1536" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastrointest Surg</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1627" to="1635" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: a propensity score matching analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Chau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Hsia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Surg</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="137" to="144" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older</title>
		<author>
			<persName><forename type="first">E</forename><surname>Tsujita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Utsunomiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ohta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Matsuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Okazaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surgery</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="696" to="703" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mirici-Cappa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gramenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Santi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zambruni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Micoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frigerio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="387" to="396" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">De novo malignancies after liver transplantation: a major cause of late death</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Fung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kusne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Dvorchik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Eghtesad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Transpl</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="S109" to="S118" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>Suppl. 1</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Increased cancer risk after liver transplantation: a population-based study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Haagsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Hagens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaapveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Van Den Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>De Vries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Klompmaker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="84" to="91" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Needle tract recurrence of hepatocellular carcinoma after liver transplantation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Dumortier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lombard-Bohas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Valette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Boillot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Scoazec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Berger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page">301</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
